Thread by @MedicalScitech

In yesterday's Covid-19 roundup: Pfizer submits EUA for Omicron-targeted booster; Novavax EUA expands to teens. endpts.com/covid-19-round…

A new generation of coronavirus vaccine, designed to be less sensitive to mutations and equipped for future strains, shows promising results in a preclinical study published in EMBO Mol. Medicine by KI researcher Matti Sällberg and colleagues. news.ki.se/new-generation…

Almost 40% of people hospitalized in the US with the Covid subvariant that circulated this spring were vaccinated and boosted, the CDC found, highlighting how new strains have mutated to more readily escape immunity. trib.al/gNyMNeC

JUST IN: China became the first country to approve a needle-free, inhaled version of a Covid vaccine made by CanSino Biologics, pushing the company’s shares up as much as 14.5% in Hong Kong trib.al/3WE2jOu

Valneva Announces Publication of its Covid-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
valneva.com/press-release/…

NEW: Novavax announced that the European Commission (EC) has approved their #COVID19Vaccine for expanded conditional marketing authorization in the European Union as a booster for adults aged 18 and older regardless of previous vaccine history. Learn more: bit.ly/3eLNgwQ

The European Court of Auditors published a report today accusing the Commission of refusing to disclose any details of president Ursula von der Leyen's personal role in the negotiations held with Pfizer over the EU’s largest coronavirus vaccine contract.
politico.eu/article/eu-sto…

The European Union drug regulator on Monday recommended authorisation for Pfizer Inc and BioNTech's COVID-19 vaccine booster updated to target the BA.4 and BA.5 subvariants of Omicron. reuters.com/business/healt…

Current talks with a potential partner on its COVID-19 jab could take several months and might not succeed, French drugmaker Valneva warned on Monday, saying it would only produce a second-generation vaccine if it obtains the necessary funding. reuters.com/business/healt…

Covid-19 roundup: Pfizer, BioNTech kick off EUA dance for teen bivalent shot; Report details slow US booster rollout endpts.com/covid-19-round…

The Indonesian food and drugs agency (BPOM) said on Thursday it has approved the emergency use of an mRNA COVID-19 vaccine developed by China's Walvax Biotechnology . reuters.com/business/healt…

Indonesia is in talks with several African countries, including Nigeria, to export and donate its homemade COVID-19 vaccine, its developer said on Friday, after becoming the first country in Southeast Asia to approve a domestically developed COVID shot. reuters.com/business/healt…

Vaccines are one of the keys to help ensure that a pandemic becomes endemic and stays that way. Read more: novav.ax/3TrXcuT

AstraZeneca's nasal spray vaccine failed to elicit a strong immune response to Covid in an early trial, a blow to the UK drug giant’s ambitions for developing an alternative approach to preventing the disease bloomberg.com/news/articles/…

A nasal version of the Oxford/AstraZeneca Covid-19 vaccine has failed in an early-stage trial, dealing a blow to hopes for a more effective way to prevent transmission of the virus. ft.com/content/4ab29e…

Attempts by Oxford University researchers and AstraZeneca Plc to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans did not yield the desired protection. reuters.com/business/healt…

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022

The committee recommended converting the conditional marketing authorisation of the COVID-19 vaccine Vaxzevria to a standard marketing authorisation. ema.europa.eu/en/news/meetin…

Moderna Inc (MRNA.O) has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world's poorest people. reuters.com/business/healt…

Nasal vaccines could still be a powerful weapon against Covid, scientists say, despite 'disappointing' trial results for an AstraZeneca spray.

China and India have already approved needle-free Covid shots, leaving some urging Western nations to catch up. today.rtl.lu/news/world/a/1…

Moderna Inc said on Wednesday its COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months. reuters.com/business/healt…

Switzerland will destroy 9 million doses of Moderna COVID-19 vaccine that have reached their expiry date, with another 5.1 million vaccine jabs set to meet the same fate by February, the government said on Wednesday. reuters.com/business/healt…

With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations. reuters.com/business/healt…

Pfizer expects to hike U.S. COVID vaccine price to $110-$130 per dose reuters.com/business/healt…

Pfizer's attempt to as much as quadruple its current U.S. prices for its COVID-19 vaccines going forward could spur revenues for years, analysts said. reuters.com/business/healt…

India vaccine maker destroys 100 million doses of expired Covid jab bbc.com/news/world-asi…

A BioNTech executive on Monday confirmed that the company is in discussions with Chinese authorities over regulatory approval of the German biotech firm's COVID-19 vaccine for use by expatriates in China but the outcome was uncertain. reuters.com/business/healt…

Data from Novavax shows that its current Covid-19 vaccine produced a better immune response than an experimental bivalent shot for omicron variants bloomberg.com/news/articles/…

Chinese pharmaceutical company CanSino Biologics said on Wednesday its inhalable Covid-19 vaccines will be available in China's northern city of Tianjin from November 10, a statement on its Wechat account said. reuters.com/business/healt…

The European Medicines Agency (EMA) on Thursday offered a positive recommendation for the first protein-based adjuvanted Covid-19 booster in Europe, developed by Sanofi and GSK.

endpts.com/ema-signs-off-…

Pfizer and its German partner BioNTech SE said their omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine. reuters.com/business/healt…

The updated Covid vaccine boosters may help older Americans, pregnant and the immunocompromised dodge serious illness and death as new virus variants spread. But early research suggests the shots are not a silver bullet for most of the population. nyti.ms/3V4NbEw

Pfizer Inc. and BioNTech SE say they have launched their BNT162b4 Phase 1 trial. The candidate, BNT162b4, is composed of a T cell antigen mRNA encoding for SARS-CoV-2 non-spike proteins that are highly conserved across a broad range of SARS-CoV-2 variants. pfizer.com/news/announcem…

Novavax Inc said on Monday it had delivered a written notice to Gavi, the Vaccine Alliance, terminating with immediate effect an agreement for the sale of the company's COVID-19 vaccine to low- and middle-income countries. reut.rs/3UVEgFZ

Global vaccine alliance Gavi said on Tuesday it was not in breach of a deal to buy Novavax's COVID-19 vaccine and that it reserved all rights, including the recovery of advance payments to the company. reut.rs/3gptl8r

EMA concludes that adapted mRNA #COVID19vaccines targeting the original strain and Omicron BA.4-5 subvariants of the SARS-CoV-2 virus may be used for initial vaccination.

These #AdaptedVaccines are currently only authorised as boosters.

Find out more ⬇️ ema.europa.eu/en/news/etf-co…

France's Haute Autorité de Santé public health body advised the government not to use Valneva's (VLS.PA) VLA2001 COVID-19 vaccine as part of its wider vaccination strategy, although two rival products should be included as booster shots. reut.rs/3iNVqHo

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022 cdc.gov/mmwr/volumes/7…

CDC & FDA Identify Preliminary COVID-19 Vaccine Safety Signal for Persons Aged 65 Years and Older
cdc.gov/coronavirus/20…

China Sinopharm said on Friday its biotech unit has received regulatory approval for clinical trials of its mRNA COVID-19 vaccine targeting the Omicron variant. reuters.com/business/healt…

https://twitter.com/Nature/status/1620838067211833368?s=20&t=RD9OHcDrIALIFqYJZS6hFQ